September 6, 2012- San Jose, California
|"Team Cytokinetics" at the
2011 South Bay Walk to Defeat ALS
Incorporated announced earlier this year that the company would be committed to
several educational and supportactivities for people with ALS and their
families throughout 2012. In addition, they will provide financial
support for special events to raise funds and increase awareness in the fight
against Lou Gehrig’s disease, and several of their employees will return to
participate in The ALS Association Golden West Chapter’s South Bay Walk
to Defeat ALS.
“Team Cytokinetics” was
started in 2010. Jeff Jasper is this year's current team captain and is
excited to return for his third walk. This year, there are about 20 team
members made up from employees of the company, as well as their families, and
friends. "Cytokinetics really encourages community participation as a part
of our corporate culture," Jasper said.
“At Cytokinetics, our dedicated employees focus our everyday activities
towards advancing a potential treatment to assist the courageous patients
suffering from this serious disease,” stated Robert I. Blum, Cytokinetics’ President
and Chief Executive Officer. “Through our ongoing Research & Development
activities on our skeletal muscle activator, tirasemtiv (formerly CK-2017357), we are exposed to patients and
caregivers that are battling this disease with persistent optimism and
hope. It is a privilege for Cytokinetics to join them to raise awareness
and important funding through community events that enable education and
continued research into the causes and
possible treatments for ALS.”
was really happy to talk with Dr. Bob Miller and Dallas Forshew at the Walk
Kick Off event," said Jasper. "It was so wonderful to be a part of
this incredible group of committed people that night. From that meeting,
I then had a chance to visit their Forbes Norris ALS Treatment and Research
Center and meet various members of the multi-disciplinary team as well as
people with ALS and their families. I am grateful for the opportunity
that attending this kick-off event provided."
presence at these events and other awareness activities has a huge impact on
our ALS community,” said Fred B. Fisher, MSW, President and CEO, The ALS
Association Golden West Chapter. “Their generous efforts support many
families struggling with Lou Gehrig’s disease, as well as advance cutting-edge
ALS research in California and around the globe.”
Cytokinetics is a clinical-stage
biopharmaceutical company focused on the discovery and development of novel
small molecule therapeutics that modulate muscle function for the potential
treatment of serious diseases and medical conditions. The company is currently
developing tirasemtiv a skeletal
muscle activator, as a potential treatment for diseases and conditions
associated with aging, muscle wasting or neuromuscular dysfunction. As reported
at the 64th annual meeting of the American Academy of Neurology this April, tirasemtiv was shown to be well
tolerated at different dosage levels for people with ALS when used in
combination with riluzole or alone. Cytokinetics plans to continue discussions
with regulatory bodies to confirm the appropriate approach to further study tirasemtiv in people with ALS.
results are encouraging, and we look forward to learning more as the clinical
trials progress,” said ALS Association Chief Scientist, Lucie Bruijn, Ph.D.
“This is a novel treatment approach and the compound's action is clearly
defined. If successful, this treatment will complement other treatment
approaches in trial,” continued Dr. Bruijn.
The company hopes the
program will move forward by the end of 2012. For more information from
Cytokinetics, visit http://tiny.cc/5boadw.
"This is such a devastating disease and we are all focused on doing 'something'
about it," said Jasper. "This sense permeates our company as a
whole, and there is real sense of urgency as it relates to working with people